Rosalie A. Scholtes
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysis.
Journal: BMJ open
Published: February 26, 2026
Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysis.
Journal: BMJ open
Published: February 26, 2026
Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial.
Journal: Diabetes, obesity & metabolism
Published: February 07, 2025
Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial.
Journal: Diabetes, obesity & metabolism
Published: January 24, 2025
Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure.
Journal: Physiological reports
Published: January 15, 2025
The systemic and kidney hemodynamic response to empagliflozin, losartan and their combination varies between individuals.
Journal: Journal of nephrology
Published: December 24, 2024
Kidney hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in diabetes: physiology and clinical implications.
Journal: Clinical kidney journal
Published: September 10, 2024
Exposure-Response Analysis of the Sodium-Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes.
Journal: Journal of personalized medicine
Published: March 11, 2023
Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial.
Journal: Diabetes, obesity & metabolism
Published: June 04, 2022
Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.
Journal: Diabetes, obesity & metabolism
Published: March 15, 2022
The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet.
Journal: Kidney international reports
Published: January 11, 2022
Last Updated: 09/26/2026